Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability.
Massimino M, Stella S, Tirrò E, Pennisi MS, Stagno F, Vitale SR, Romano C, Tomarchio C, Parrinello NL, Manzella L, Di Raimondo F, Vigneri P. Massimino M, et al. Among authors: stagno f. Onco Targets Ther. 2023 Oct 3;16:803-816. doi: 10.2147/OTT.S413825. eCollection 2023. Onco Targets Ther. 2023. PMID: 37807980 Free PMC article.
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, Galimberti S, Gozzini A, Gugliotta G, Iurlo A, Latagliata R, Luciano L, Pregno P, Rege-Cambrin G, Rosti G, Stagno F, Tiribelli M, Foà R, Saglio G; Campus CML working group. Breccia M, et al. Among authors: stagno f. Leukemia. 2020 Aug;34(8):2260-2261. doi: 10.1038/s41375-020-0904-z. Epub 2020 Jun 18. Leukemia. 2020. PMID: 32555369 Free PMC article. No abstract available.
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Russo Rossi A, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G. Russo Rossi A, et al. Among authors: stagno f. Haematologica. 2013 Mar;98(3):399-403. doi: 10.3324/haematol.2012.064337. Epub 2012 Jul 16. Haematologica. 2013. PMID: 22801965 Free PMC article.
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, Isidori A. Visani G, et al. Among authors: stagno f. Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871. Am J Hematol. 2010. PMID: 21069865 Free article. No abstract available.
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F. Efficace F, et al. Among authors: stagno f. Leukemia. 2013 Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18. Leukemia. 2013. PMID: 23417029
153 results